![Jonathan Smith](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Jonathan Smith
Direttore/Membro del Consiglio presso Wound Ostomy Continence Nursing Certification Board
Posizioni attive di Jonathan Smith
Società | Posizione | Inizio | Fine |
---|---|---|---|
Wound Ostomy Continence Nursing Certification Board | Direttore/Membro del Consiglio | - | - |
Storia della carriera di Jonathan Smith
Precedenti posizioni note di Jonathan Smith
Società | Posizione | Inizio | Fine |
---|---|---|---|
Emergent Travel Health, Inc.
![]() Emergent Travel Health, Inc. Internet Software/ServicesTechnology Services Emergent Travel Health, Inc. develops vaccines against infectious diseases. The firm develops vaccines against typhoid, cholera, hepatitis, anthrax, and other infectious diseases. Its proprietary adenoviral-based technology platform enables the rapid development of oral vaccines that can target viral or bacterial protein antigen. The company was founded by Kenneth Kelley and Daniel R. Henderson in 2007 and is headquartered in San Diego, CA. | Direttore Tecnico/Scientifico/R&S | 01/01/2012 | 01/12/2018 |
U.S. Army Medical Research Institute for Infectious Diseases | Corporate Officer/Principal | - | - |
University of Maryland | Corporate Officer/Principal | - | - |
AlphaVax, Inc.
![]() AlphaVax, Inc. Pharmaceuticals: MajorHealth Technology AlphaVax, Inc. involves in clinical-stage biopharmaceutical company. It develops vaccine technology bio products. The firm products include Alphavax and pipleline bio products. It focuses on commercial potential of its alphavaccine vector technology in cancer immunotherapy. The company was founded in 1997 and is headquartered in Durham, NC. | Direttore Tecnico/Scientifico/R&S | - | - |
Fondatore | - | - | |
Liquidia Technologies, Inc.
![]() Liquidia Technologies, Inc. Pharmaceuticals: MajorHealth Technology Liquidia Technologies, Inc. is a clinical biopharmaceutical company focused on the development and commercialization of human therapeutics using its proprietary PRINT technology to transform the lives of patients. It operates in two segments: Pharmaceutical Products and Partnering & Licensing. The two product candidates from its pipeline: LIQ861 for the treatment of pulmonary arterial hypertension and LIQ865 for the treatment of local post-operative pain. Liquidia Technologies was founded by Joseph M. DeSimone, Ashok K. Mendiratta, Edward T. Samulski, William R. Kenan, Ginger Denison and Jason Rolland in 2004 and is headquartered in Morrisville, NC. | Direttore Tecnico/Scientifico/R&S | 16/04/2010 | - |
Formazione di Jonathan Smith
Colby College | Undergraduate Degree |
The University of Texas at Austin | Doctorate Degree |
Statistiche
Distribuzione geografica
Stati Uniti | 9 |
Posizioni
Chief Tech/Sci/R&D Officer | 3 |
Corporate Officer/Principal | 2 |
Undergraduate Degree | 1 |
Settori
Consumer Services | 5 |
Health Technology | 3 |
Technology Services | 2 |
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Società collegate
Aziende private | 4 |
---|---|
Liquidia Technologies, Inc.
![]() Liquidia Technologies, Inc. Pharmaceuticals: MajorHealth Technology Liquidia Technologies, Inc. is a clinical biopharmaceutical company focused on the development and commercialization of human therapeutics using its proprietary PRINT technology to transform the lives of patients. It operates in two segments: Pharmaceutical Products and Partnering & Licensing. The two product candidates from its pipeline: LIQ861 for the treatment of pulmonary arterial hypertension and LIQ865 for the treatment of local post-operative pain. Liquidia Technologies was founded by Joseph M. DeSimone, Ashok K. Mendiratta, Edward T. Samulski, William R. Kenan, Ginger Denison and Jason Rolland in 2004 and is headquartered in Morrisville, NC. | Health Technology |
Emergent Travel Health, Inc.
![]() Emergent Travel Health, Inc. Internet Software/ServicesTechnology Services Emergent Travel Health, Inc. develops vaccines against infectious diseases. The firm develops vaccines against typhoid, cholera, hepatitis, anthrax, and other infectious diseases. Its proprietary adenoviral-based technology platform enables the rapid development of oral vaccines that can target viral or bacterial protein antigen. The company was founded by Kenneth Kelley and Daniel R. Henderson in 2007 and is headquartered in San Diego, CA. | Technology Services |
AlphaVax, Inc.
![]() AlphaVax, Inc. Pharmaceuticals: MajorHealth Technology AlphaVax, Inc. involves in clinical-stage biopharmaceutical company. It develops vaccine technology bio products. The firm products include Alphavax and pipleline bio products. It focuses on commercial potential of its alphavaccine vector technology in cancer immunotherapy. The company was founded in 1997 and is headquartered in Durham, NC. | Health Technology |
Wound Ostomy Continence Nursing Certification Board |
- Borsa valori
- Insiders
- Jonathan Smith
- Esperienza